- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04076514
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma (pCND)
July 10, 2020 updated by: Ahmed Kamel Ali, Assiut University
The benefits of prophylactic central neck dissection (pCND) remain controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC).
This study main goal is to investigate benefits of prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma.
Recurrence rate is still high.
The standard management is total thyroidectomy.
regional lymph node metastasis is noted in recurrent cases.
Some studies stated benefits of central neck dissection in orevention of recurrence and others said there is no benefits.
so prophylactic central neck dissection (pCND) remain controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC).
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: ahmed kamel ali
- Phone Number: 00201021259455
- Email: ahmed01155@med.aun.edu.eg
Study Locations
-
-
Asyut
-
Asyūţ, Asyut, Egypt
- Recruiting
- Ahmed Kamel
-
Contact:
- ahmed kamel ali
- Phone Number: 00201021259455
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients with papillary thyroid carcinoma with clinically negative lymph node who undergo total thyroidectomy and central neck dissetion in assiut university hospital, department of general surgery.
Description
Inclusion Criteria:
- patients with papillary thyroid cancer with clinically node negative.
Exclusion Criteria:
- patients with clinical evidence of nodal metastases.
- patients with a previous history of thyroidectomy.
- patients with mixed-type papillary thyroid cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with node negative papillary thyroid carcinoma
|
dissection of central cervical lymph node grope in low grade papillary thyroid cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the incidence metastatic lymph node in patients with clinically node-negative thyroid carcinoma who underwent total thyroidectomy with central neck dissection
Time Frame: 12 months
|
numbers of positive histopathological lymph node biopsies postoperative
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 1, 2020
Primary Completion (ANTICIPATED)
September 30, 2020
Study Completion (ANTICIPATED)
November 1, 2020
Study Registration Dates
First Submitted
August 28, 2019
First Submitted That Met QC Criteria
August 30, 2019
First Posted (ACTUAL)
September 3, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 14, 2020
Last Update Submitted That Met QC Criteria
July 10, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ahmed1712
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillary Thyroid Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage II Papillary Thyroid Cancer | Stage III Papillary Thyroid Cancer | Stage I Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsRecruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
-
Mayo ClinicActive, not recruitingPapillary Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
Grupo Espanol de Tumores NeuroendocrinosMFARActive, not recruitingMetastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular CarcinomaSpain
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
Clinical Trials on central neck dissection
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Samsung Medical CenterUnknownCarcinomaKorea, Republic of
-
Guang-Yan YuNational Natural Science Foundation of China; Peking University School of StomatologyRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedPatients With Papillary Thyroid Cancer and N1b StatusItaly
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruitingOral Squamous Cell Carcinoma | Neck Dissection
-
Cancer Institute and Hospital, Chinese Academy...Jilin Provincial Tumor Hospital; Hebei Medical University Fourth Hospital; Liaoning... and other collaboratorsUnknownLaryngeal Neoplasms | Malignant Neoplasm of Supraglottis Primary | Neck DislocationChina
-
Centro de Excelencia en Enfermedades de Cabeza...Hospital San Vicente Fundación; Hospital Alma Mater de Antioquia; Clinica Las...Recruiting
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...UnknownOral Squamous Cell CarcinomaChina
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting